Status:

TERMINATED

A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer

Lead Sponsor:

AHS Cancer Control Alberta

Conditions:

Breast Neoplasm

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

In about half the cases of breast cancer, there is hypoxic (no, or little oxygen) tissue present. Hypoxic cells can be resistant to treatment and may cause increased tumour growth. This study will use...

Detailed Description

Hypoxia or anoxia can be found in 50% of locally advanced breast carcinomas. Assessment of pre-treatment in viva and in vitro hypoxia could allow patient selection for more aggressive therapy or clini...

Eligibility Criteria

Inclusion

  • Female ≥ 18 years of age. If female of child bearing potential and if outside of the window of 10 days since the first day of the 0last menstrual period, patient will be required to have a negative pregnancy test.
  • Pathologically proven invasive duct carcinoma of the breast (FNA or core biopsy), T1-T4(T ≥ 1.5 cm)
  • FluGlucoScan Injection and 18F-FAZA PET scans performed prior to treatment.
  • FluGlucoScan Injection and 18F-FAZA PET scans performed within 4 weeks prior to their definitive surgery if subject does not have neoadjuvant therapy.
  • Able and willing to follow instructions and comply with the protocol
  • Provide written informed consent prior to participation in the study.
  • ECOG performance score ≤ 2

Exclusion

  • Previous malignancy or diagnosis less than ten (10) years ago. Skin Cancers (excluding malignant melanoma) and carcinoma in situ of the cervix are exceptions.
  • Excisional biopsy of the primary breast tumour has been performed
  • Women with an invasive carcinoma of the breast that is not predominantly of the invasive duct subtype
  • Primary breast carcinoma previously treated.
  • Women who are nursing or pregnant.

Key Trial Info

Start Date :

November 28 2008

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 4 2019

Estimated Enrollment :

23 Patients enrolled

Trial Details

Trial ID

NCT00771381

Start Date

November 28 2008

End Date

February 4 2019

Last Update

August 22 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Cross Cancer Institute

Edmonton, Alberta, Canada, T6G 1Z2